放疗中期18F-氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描在食管癌中的意义
本研究纳入2015至2020年间接受放疗(联合或不联合化疗)的83例食管癌患者,分析放疗中期FDG PET/CT代谢参数(MTV、TLG、SUVmean、SUVmax)对局部区域无复发生存率(LRFR)和远处无转移生存率(DMFR)的预测价值。中位随访10.5个月,放疗中期SUVmax与LRFR(HR 1.07,p=0.009)和DMFR(HR 1.13,p=0.047)显著相关,MTV与DMFR相关(HR 1.06,p=0.007)。作者认为放疗期间肿瘤代谢变化可作为治疗反应和复发的有用预测工具,临床医生可考虑在放疗期间进行早期PET疗效评估。
要点
- 放疗中期SUVmax≤11患者1年LRFR 73.4% vs >11者48.4%(p=0.028)。
- 放疗中期SUVmax≤11患者1年DMFR 74.6% vs >11者40.7%(p=0.007)。
- 放疗中期MTV≤15患者1年DMFR 78.2% vs >15者31.9%(p=0.002)。
核心结论
- 放疗期间肿瘤代谢变化可作为食管癌患者治疗反应和复发的有用预测工具。
- 临床医生可考虑在放疗期间进行早期PET疗效评估以预测预后信息(作者建议)。
研究设计与样本
- 纳入2015至2020年间接受放疗联合或不联合化疗的83例食管癌患者。
- 分析FDG PET/CT代谢参数包括代谢肿瘤体积(MTV)、总病灶糖酵解、平均标准化摄取值(SUVmean)和最大标准化摄取值(SUVmax)。
- 分析局部区域无复发生存率(LRFR)和远处无转移生存率(DMFR)。
主要发现
- 中位随访时间为10.5个月。
- 放疗中期SUVmax与LRFR显著相关(HR 1.07,p=0.009),与DMFR显著相关(HR 1.13,p=0.047)。
- 放疗中期MTV与DMFR显著相关(HR 1.06,p=0.007)。
- 放疗后治疗反应与总生存显著相关(HR 1.52,p=0.025)。
- 治疗反应与放疗中期SUVmax显著相关。
关键数值与推荐
- 预测LRFR和DMFR的放疗中期SUVmax最佳截断值为11。
- 放疗中期MTV最佳截断值为15。
- 放疗中期SUVmax≤11患者1年LRFR为73.4%,SUVmax>11患者为48.4%(p=0.028)。
- 放疗中期SUVmax≤11患者1年DMFR为74.6%,SUVmax>11患者为40.7%(p=0.007)。
- 放疗中期MTV≤15患者1年DMFR为78.2%,MTV>15患者为31.9%(p=0.002)。
临床怎么用
- 作者认为放疗期间肿瘤代谢变化可作为食管癌治疗反应和复发的有用预测工具。
- 作者建议临床医生可考虑在放疗期间进行早期PET疗效评估以预测预后信息。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Metabolic parameters evaluated by 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) are known as prognostic markers in various cancers. We aimed to validate the predictive value of mid-radiotherapy (RT) FDG PET/CT parameters in esophageal cancer. MATERIALS AND METHODS: Eighty-three patients treated with RT with or without chemotherapy between 2015 and 2020 were included. PET parameters including metabolic tumor volume (MTV), total lesion glycolysis, and mean (SUVmean) and maximum standardized uptake value (SUVmax) were analyzed. Locoregional recurrence-free rate (LRFR) and distant metastasis-free rate (DMFR) were analyzed. RESULTS: The median follow-up period was 10.5 months. Mid-RT SUVmax was significantly associated with LRFR (HR 1.07, p = 0.009) and DMFR (HR 1.13, p = 0.047) while mid-RT MTV was associated with DMFR (HR 1.06, p = 0.007). Treatment response after RT was associated with overall survival (HR, 1.52, p = 0.025). Further, treatment response was significantly associated with mid-RT SUVmax. The optimal cutoff value for mid-RT SUVmax in predicting LRFR and DMFR was 11 while cutoff value for mid-RT MTV was 15. The patients with mid-RT SUVmax ≤ 11 showed superior LRFR and DMFR compared to SUVmax > 11 (1-year LRFR; 73.4% vs. 48.4%, p = 0.028, 1-year DMFR; 74.6% vs. 40.7%, p = 0.007). The 1-year DMFR was significantly different between patients with mid-RT MTV ≤ 15 and >15 (1-year DMFR; 78.2% vs. 31.9%, p = 0.002). CONCLUSION: Tumor metabolism changes during RT can be a useful predictive tool for treatment response and recurrence in patients with esophageal cancer. Clinicians may consider early response evaluation with PET during RT for predicting prognosis information about prognosis.
引用
- Lee BM, Lee CG. Significance of mid-radiotherapy 18F-fluorodeoxyglucose positron emission tomography/computed tomography in esophageal cancer. Radiother Oncol. 2022. PMID: 35447284. doi:10.1016/j.radonc.2022.04.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。